文献速递艾滋病与性传播感染

南非HIV疫苗试验网络702 2b-3期HIV-1疫苗试验分析:评估RV144抗体与T细胞相关免疫标志与HIV-1感染风险的关系

Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
PubMed 文献 · J Infect Dis · 2022-01-01

在HVTN 702试验的1893名女性疫苗接种者中抽取60例HIV-1血清阳性病例和60名匹配的血清阴性非病例,检测第四、五次免疫后2周的HIV特异性CD4+ T细胞和结合抗体反应。HVTN 702的Env特异性CD4+ T细胞反应率显著高于RV144(63% vs 40%,P = .03),而针对1086.C V1V2的IgG结合抗体反应率和幅度显著低于RV144(67% vs 100%,P < .001;Pmag < .001)。虽无显著单变量关联,但观察到显著交互作用(多重校正P ≤.03);在IgG A244 V1V2结合抗体反应高的疫苗者中,疫苗匹配的CD4+ T细胞终点与HIV-1感染风险降低相关(估计风险比=0.40-0.49每1-SD增加)。

要点

  • HVTN 702与RV144免疫原性特征不同:CD4+ T细胞反应率63% vs 40%,P = .03。
  • 针对1086.C V1V2的IgG结合抗体反应率和幅度显著低于RV144(67% vs 100%,P < .001)。
  • 在IgG A244 V1V2结合抗体反应高者中,CD4+ T细胞终点与HIV-1感染风险降低相关(估计HR=0.40-0.49)。

核心结论

  • HVTN 702与RV144具有不同的免疫原性特征,但两者均发现IgG V1V2和多功能性CD4+ T细胞与HIV-1感染风险存在显著相关性(单变量或交互作用)。

研究设计与样本

  • 在1893名HVTN 702女性疫苗接种者中,抽取60例HIV-1血清阳性病例和60名匹配的血清阴性非病例。
  • 在第四和第五次免疫后2周检测HIV特异性CD4+ T细胞和结合抗体反应。
  • 采用Cox比例风险模型评估预设免疫反应作为HIV-1感染风险的预测因子。

主要发现

  • HVTN 702的Env特异性CD4+ T细胞反应率显著高于RV144(63% vs 40%,P = .03)。
  • HVTN 702针对1086.C V1V2的IgG结合抗体反应率和幅度显著低于RV144(67% vs 100%,P < .001;Pmag < .001)。
  • 任何T细胞或结合抗体反应与HIV-1感染之间均未观察到显著的单变量关联。
  • 观察到显著的交互作用(多重校正P ≤.03)。
  • 在IgG A244 V1V2结合抗体反应高的疫苗者中,疫苗匹配的CD4+ T细胞终点与HIV-1感染风险降低相关(估计风险比=0.40-0.49每1-SD增加)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk in RV144 were measured in HVTN 702 and evaluated as correlates of HIV-1 acquisition. METHODS: Among 1893 HVTN 702 female vaccinees, 60 HIV-1-seropositive cases and 60 matched seronegative noncases were sampled. HIV-specific CD4+ T-cell and binding antibody responses were measured 2 weeks after fourth and fifth immunizations. Cox proportional hazards models assessed prespecified responses as predictors of HIV-1 acquisition. RESULTS: The HVTN 702 Env-specific CD4+ T-cell response rate was significantly higher than in RV144 (63% vs 40%, P = .03) with significantly lower IgG binding antibody response rate and magnitude to 1086.C V1V2 (67% vs 100%, P < .001; Pmag < .001). Although no significant univariate associations were observed between any T-cell or binding antibody response and HIV-1 acquisition, significant interactions were observed (multiplicity-adjusted P ≤.03). Among vaccinees with high IgG A244 V1V2 binding antibody responses, vaccine-matched CD4+ T-cell endpoints associated with decreased HIV-1 acquisition (estimated hazard ratios = 0.40-0.49 per 1-SD increase in CD4+ T-cell endpoint). CONCLUSIONS: HVTN 702 and RV144 had distinct immunogenicity profiles. However, both identified significant correlations (univariate or interaction) for IgG V1V2 and polyfunctional CD4+ T cells with HIV-1 acquisition. Clinical Trials Registration . NCT02968849.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Moodie Z, Dintwe O, Sawant S, et al. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J Infect Dis. 2022. PMID: 35758878. doi:10.1093/infdis/jiac260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。